| Type | Public |
|---|---|
| Founded | 2007 |
| Headquarters | Cambridge, Massachusetts, United States |
| Key people | Carlos A. Riva, President & CEO John A. McCarthy, Jr., Exec. VP & CFO |
Verenium Corporation, (NASDAQ: VRNM) is a Cambridge, Massachusetts-based biotechnology company that specialized in metagenomics and the development of high performance specialty enzymes for applications in biofuels and other industrial applications. Formerly separate firms Diversa and Celunol, Verenium Corporation was created by the former two firms' merger in 2007.
According to the Economist article listed in the "References" section, Diversa prospects in hot springs, ocean beds, soda lakes, and on the Arctic tundra for genes potentially useful in industry.
In February 2007, Diversa announced a merger with Celunol, a leading corporation in the emerging cellulosic ethanol industry. Celunol had received substantial backing from Silicon Valley venture capitalist Vinod Khosla. The buyout was financed by approximately 15 million shares of Diversa stock plus up to $20 million in debt financing to fund Celunol operations. After the merger, Khosla became one of the largest single shareholders of the new company.[1]
Contents |
Cellulosic Ethanol Production
Verenium's demonstration scale biorefinery, built to produce 1.4 million gallons of ethanol a year from cellulosic biomass opened in Jennings, LA on the 29th of May 2008. The plant makes ethanol from agricultural waste left over from processing sugarcane.[2]
See also
References
- ^ "Sea of dreams: Genetically modified microbes will lead to a revolution in industrial biotechnology", an article on page eighty-one of the 1 May 2004 issue of The Economist
- ^ Bullis Kevin. "Cellulosic Ethanol Plant Opens" Technology Review 28 May 2008
External links
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
